Myeloma

The phase III DREAMM-7 trial evaluated the efficacy and safety of belantamab mafodotin plus bortezomib and dexamethasone (BVd) compared to daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM) patients with ≥1 prior therapy. Involving 494 patients, the study found that BVd significantly improved progression-free survival (PFS) (36.6 months versus 13.4 months) and showed a strong trend towards improved overall survival (OS). BVd also resulted in a higher overall response rate (82.7% versus 71.3%) and longer median duration of response (35.6 months versus 17.8 months). Grade 3/4 adverse events were higher in the BVd group (90% versus 67%), including more frequent but manageable ocular events. These results support BVd as a potential new standard of care for RRMM.

touchHAEMATOLOGY coverage of data presented at EHA 2024: The phase I/II CAMMA 2 study evaluates cevostamab, a bispecific antibody targeting FcRH5xCD3, in patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class refractory and have received prior B-cell maturation antigen (BCMA)-targeted therapy. Initial results from Cohort A1 (21 patients) show a 67% overall response rate (ORR), […]

The 29th European Hematology Association (EHA) 2024 Congress was held on 13–16th June 2024 in Madrid, Spain. As with every year, the EHA Congress covered a wide array of topics in haematology and haematological malignancies. Key data presented at the congress not only highlighted significant advancements in these areas but also provided insights that could shape future clinical practices.

We delve into the exploratory analysis of the DETERMINATION study data, which suggests a potential meaningful progression-free survival (PFS) benefit for African American (AA) patients receiving RVd-alone treatment. We also examine safety findings, noting a similar safety profile between AA and White patients, despite the high prevalence of Duffy-null alleles in AA patients. However, we observe that neuropathic toxicity may be higher in AA patients. Finally, we discuss how these clinical insights could influence treatment decisions for newly diagnosed multiple myeloma patients